# The Impact of Genetics on Pediatric Interstitial Lung Diseases: A Narrative Literature Review and Clinical Implications

**Authors:** Martina Mazzoni, Sonia Lomuscio, Adriano La Vecchia, Rosamaria Terracciano, Fabio Antonelli, Pierluigi Vuilleumier, Annalisa Allegorico

PMC · DOI: 10.3390/biomedicines14020385 · Biomedicines · 2026-02-06

## TL;DR

This paper reviews how genetic factors influence pediatric interstitial lung diseases and how this knowledge can improve diagnosis and treatment.

## Contribution

The paper synthesizes recent genetic findings in pediatric ILDs and emphasizes their clinical implications for precision medicine.

## Key findings

- Over 30 genes with various inheritance patterns are linked to ILD pathogenesis.
- Genetic insights can improve diagnostic accuracy and inform therapeutic strategies.
- Incomplete genotype–phenotype correlations and limited functional validation remain challenges.

## Abstract

Background: Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by variable degrees of inflammation and fibrosis affecting the pulmonary interstitium. Advances in molecular biology and genetics have greatly expanded our understanding of ILD pathogenesis, uncovering novel mechanisms and supporting precision medicine approaches. Genetic Insights: Genetic factors play a pivotal role in ILD heterogeneity, influencing disease onset, severity, and progression. To date, more than 30 genes with different inheritance patterns (autosomal dominant, recessive, or X-linked) have been associated with ILDs. These genes are primarily involved in surfactant metabolism, telomere maintenance, immune regulation, and epithelial repair. Emerging evidence also implicates genes encoding aminoacyl-tRNA synthetases. This review summarizes the main genetic alterations underlying ILD pathogenesis and discusses their impact on diagnostic and therapeutic approaches, highlighting how identification of disease-causing variants can improve diagnostic accuracy, refine prognostic assessment, and inform recurrence risk. Methods: A narrative review was conducted through targeted PubMed and Embase searches using disease- and gene-related keywords. Studies were prioritized based on predefined conceptual criteria, including clinical relevance, strength and replication of genetic associations, and availability of functional or translational evidence. Conclusions: This synthesis brings together the latest genetic insights into pediatric ILDs and their clinical implications. Integrating genomic data into clinical practice may enable earlier diagnosis, tailored follow-up, individualized therapeutic strategies, and more informed genetic counseling. However, important challenges remain, including incomplete genotype–phenotype correlations and limited functional validation for several disease-associated genes, which currently constrain full clinical translation.

## Full-text entities

- **Genes:** SFTPC (surfactant protein C) [NCBI Gene 6440] {aka BRICD6, PSP-C, SFTP2, SMDP2, SP-C}, CSF2RA (colony stimulating factor 2 receptor subunit alpha) [NCBI Gene 1438] {aka CD116, CDw116, CSF2R, CSF2RAX, CSF2RAY, CSF2RX}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, NHLRC2 (NHL repeat containing 2) [NCBI Gene 374354] {aka FINCA}, ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, FAM111B (FAM111 trypsin like peptidase B) [NCBI Gene 374393] {aka CANP, POIKTMP}, RTEL1 (regulator of telomere elongation helicase 1) [NCBI Gene 51750] {aka C20orf41, DKCA4, DKCB5, NHL, PFBMFT3, RTEL}, ADRA2B (adrenoceptor alpha 2B) [NCBI Gene 151] {aka ADRA2L1, ADRA2RL1, ADRARL1, ALPHA2BAR, FAME2, alpha-2BAR}, RNASEL (ribonuclease L) [NCBI Gene 6041] {aka PRCA1, RNS4}, NOP10 (NOP10 ribonucleoprotein) [NCBI Gene 55505] {aka CHINE2, DKCB1, NOLA3, NOP10P, PFBMFT9}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, COPA (coat protein complex I subunit alpha) [NCBI Gene 1314] {aka AIAISD, AIAISD1, AILJK, HEP-COP, alpha-COP}, LARS1 (leucyl-tRNA synthetase 1) [NCBI Gene 51520] {aka HSPC192, ILFS1, LARS, LEURS, LEUS, LFIS}, FOXF1 (forkhead box F1) [NCBI Gene 2294] {aka ACDMPV, FKHL5, FREAC1}, DKC1 (dyskerin pseudouridine synthase 1) [NCBI Gene 1736] {aka CBF5, CHINE1, DKC, DKCX, NAP57, NOLA4}, ARHGAP42 (Rho GTPase activating protein 42) [NCBI Gene 143872] {aka AD031, GRAF3, TMEM133}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, SFTPD (surfactant protein D) [NCBI Gene 6441] {aka COLEC7, PSP-D, SFTP4, SP-D}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, FARSA (phenylalanyl-tRNA synthetase subunit alpha) [NCBI Gene 2193] {aka CML33, FARSL, FARSLA, FRSA, PheHA, RILDBC2}, FGF10 (fibroblast growth factor 10) [NCBI Gene 2255] {aka LADD3}, IARS1 (isoleucyl-tRNA synthetase 1) [NCBI Gene 3376] {aka GRIDHH, IARS, ILERS, ILRS, IRS, PRO0785}, TREX1 (three prime repair exonuclease 1) [NCBI Gene 11277] {aka AGS1, CRV, DRN3, HERNS, RVCLS}, GATA2 (GATA binding protein 2) [NCBI Gene 2624] {aka DCML, IMD21, MONOMAC, NFE1B}, MUC5B (mucin 5B, oligomeric mucus/gel-forming) [NCBI Gene 727897] {aka MG1, MUC-5B, MUC5, MUC9}, FARS2 (phenylalanyl-tRNA synthetase 2, mitochondrial) [NCBI Gene 10667] {aka COXPD14, FARS1, HSPC320, PheRS, SPG77, mtPheRS}, OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938] {aka E18/E16, IFI-4, IMD100, OIAS, OIASI}, CSF2RB (colony stimulating factor 2 receptor subunit beta) [NCBI Gene 1439] {aka CD131, CDw131, IL3RB, IL5RB, SMDP5, betaGMR}, SFTPA2 (surfactant protein A2) [NCBI Gene 729238] {aka COLEC5, ILD2, PSAP, PSP-A, PSPA, SFTP1}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, AP3B1 (adaptor related protein complex 3 subunit beta 1) [NCBI Gene 8546] {aka ADTB3, ADTB3A, HPS, HPS2, PE}, FARSB (phenylalanyl-tRNA synthetase subunit beta) [NCBI Gene 10056] {aka FARSLB, FRSB, HSPC173, NEDBLLA, PheHB, PheRS}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, YARS1 (tyrosyl-tRNA synthetase 1) [NCBI Gene 8565] {aka CMTDIC, IMNEPD2, TYRRS, YARS, YRS, YTS}, POT1 (protection of telomeres 1) [NCBI Gene 25913] {aka CMM10, CRMCC3, GLM9, HPOT1, PFBMFT8, TPDS3}, TBX4 (T-box transcription factor 4) [NCBI Gene 9496] {aka ICPPS, PAPPAS, SPS}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, mucin [NCBI Gene 100508689], NKX2-1 (NK2 homeobox 1) [NCBI Gene 7080] {aka BCH, BHC, NK-2, NKX2.1, NKX2A, NMTC1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, STAT5B (signal transducer and activator of transcription 5B) [NCBI Gene 6777] {aka GHISID2, STAT5}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, LAMP3 (lysosome associated membrane protein 3) [NCBI Gene 27074] {aka CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3}, ITGA3 (integrin subunit alpha 3) [NCBI Gene 3675] {aka CD49C, FRP-2, GAP-B3, GAPB3, ILNEB, JEB7}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, GRN (granulin precursor) [NCBI Gene 2896] {aka CLN11, FTD2, GEP, GP88, PCDGF, PEPI}, SFTPB (surfactant protein B) [NCBI Gene 6439] {aka PSP-B, SFTB3, SFTP3, SMDP1, SP-B}, SMOC1 (SPARC related modular calcium binding 1) [NCBI Gene 64093] {aka OAS}, PARN (poly(A)-specific ribonuclease) [NCBI Gene 5073] {aka DAN, DKCB6, PFBMFT4}, ABCA3 (ATP binding cassette subfamily A member 3) [NCBI Gene 21] {aka ABC-C, ABC3, EST111653, LBM180, SMDP3}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, ABCD1 (ATP binding cassette subfamily D member 1) [NCBI Gene 215] {aka ABC42, ALD, ALDP, AMN}, GRP (gastrin releasing peptide) [NCBI Gene 2922] {aka BN, GRP-10, preproGRP, proGRP}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, FLNA (filamin A) [NCBI Gene 2316] {aka ABP-280, ABPX, CSBS, CVD1, FGS2, FLN}, SFTPA1 (surfactant protein A1) [NCBI Gene 653509] {aka COLEC4, ILD1, PSP-A, PSPA, SFTP1, SFTPA1B}, MARS1 (methionyl-tRNA synthetase 1) [NCBI Gene 4141] {aka CMT2U, ILFS2, ILLD, MARS, METRS, MRS}, TINF2 (TERF1 interacting nuclear factor 2) [NCBI Gene 26277] {aka DKCA3, DKCA5, TIN2}
- **Diseases:** premature graying (MESH:C536859), interstitial disorder (MESH:D065167), failure to (MESH:D051437), deafness (MESH:D003638), congenital mydriasis (MESH:C563221), vasculopathy (MESH:D000090122), congenital hypothyroidism (MESH:D003409), ocular abnormalities (MESH:D005124), airway infections (MESH:D007239), ATS (MESH:D050030), bronchitis (MESH:D001991), Hamman-Rich syndrome (MESH:D000080203), cleft palate (MESH:D002972), Rajab interstitial lung disease with brain calcifications 1 and 2 (OMIM:613658), IPF (MESH:D054990), lung cancer (MESH:D008175), cardiovascular disease (MESH:D002318), Dyspnea (MESH:D004417), sarcoidosis (MESH:D012507), bone-marrow dysfunction (MESH:D001855), Failure to thrive (MESH:D005183), gastrointestinal and hepatic involvement (MESH:D005767), post-infectious injury (MESH:D000094025), end-stage respiratory failure (MESH:D007676), immune (MESH:D007154), pancytopenia (MESH:D010198), Pulmonary disease (MESH:D008171), chromosomal abnormalities (MESH:D002869), contiguous-gene deletion condition (MESH:D002872), skin fragility (MESH:C536183), cancer (MESH:D009369), endocrine abnormalities (MESH:D004700), idiopathic pulmonary hypertension (MESH:D065627), cerebrovascular anomalies (MESH:D002561), Cough (MESH:D003371), Growth hormone insensitivity with immune dysregulation 1 (MESH:C537871), bronchopulmonary dysplasia (MESH:D001997), pulmonary edema (MESH:D011654), phimosis (MESH:D010688), toxicity (MESH:D064420), lung and liver fibrosis (MESH:D008103), cystic fibrosis (MESH:D003550), hair (MESH:D006201), neurodevelopmental abnormalities (MESH:D063647), autosomal dominant condition (MESH:C566739), weight loss (MESH:D015431), osteoporosis (MESH:D010024), Ischiocoxopodopatellar syndrome (MESH:C535540), CAD (MESH:C536590), emphysema (MESH:D004646), congenital heart disease (MESH:D006330), Alveolar capillary dysplasia with misalignment (MESH:D010547), edema (MESH:D004487), NEHI (MESH:D018278), graft-versus-host disease (MESH:D006086), pectus carinatum (MESH:D066166), tachypnea (MESH:D059246), chest wall deformity (MESH:D013898), lung injury (MESH:D055370), anxiety (MESH:D001007)
- **Chemicals:** pirfenidone (MESH:C093844), 4-phenylbutyrate (MESH:C075773), Rituximab (MESH:D000069283), azathioprine (MESH:D001379), rapamycin (MESH:D020123), carbon (MESH:D002244), Janus (-), mycophenolate mofetil (MESH:D009173), belimumab (MESH:C511911), HCQ (MESH:D006886), Oxygen (MESH:D010100), tocilizumab (MESH:C502936), baricitinib (MESH:C000596027), (A) (MESH:D001151), ruxolitinib (MESH:C540383), nintedanib (MESH:C530716), cholesterol (MESH:D002784), trehalose (MESH:D014199), ROS (MESH:D017382), danazol (MESH:D003613), steroid (MESH:D013256), lipid (MESH:D008055), iron (MESH:D007501), glycogen (MESH:D006003), carbamazepine (MESH:D002220)
- **Species:** Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]
- **Mutations:** X-Y, cysteine/serine, p.Leu45Arg, c.325-47_374del, Y140X

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938008/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938008/full.md

## References

112 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938008/full.md

---
Source: https://tomesphere.com/paper/PMC12938008